Impact Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• IMP4927 · Oncology
  IMP4927 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage infiltration and activation in the tumor microenvironment.

Phase 2 pipeline

• IMP4297

Phase 1 pipeline

• 14C-IMP4297
• IMP7068
• IMP9064

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Impact Therapeutics, Inc. portfolio CI brief
• Impact Therapeutics, Inc. pipeline updates RSS